Local production will permit CAR-T treatment to be available free of charge to patients.
The cost to the Brazilian public health system will be slashed to 10% of the amount currently charged in Europe and the USA (only US$35,000 per dose).
RIO DE JANEIRO and GAITHERSBURG, Md., March 26, 2024 — Fundação Oswaldo Cruz (Fiocruz), a foundation from the Brazilian government’s Ministry of Health, and Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to advanced medicinal cures for all patients, everywhere, today announced a collaboration to develop local manufacturing of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil, including CAR-T cell therapies for leukemia, lymphoma, and HIV infection. [Read more…]